Baird Financial Group
FATE icon

Baird Financial Group’s Fate Therapeutics FATE Stock Holding History

Baird Financial Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,801
Closed -$225K – 1797
2022
Q1 		$225K Buy
5,801
+1,892
+48% +$73.3K ﹤0.01% 1716
2021
Q4 		$229K Hold
3,909
– – ﹤0.01% 1778
2021
Q3 		$232K Buy
+3,909
New +$307K ﹤0.01% 1759

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Baird Financial Group's FATE Position: Q2 2022 in Review

Baird Financial Group sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 5,801 shares — an estimated $225K sold.

Baird Financial Group first reported a position in FATE in Q3 2021 and held it in 3 quarters. The position peaked at $232K in Q3 2021. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Baird Financial Group reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Baird Financial Group sold 5,801 Fate Therapeutics shares in Q2 2022, an estimated $225K.
  • Baird Financial Group first reported a position in Fate Therapeutics in Q3 2021 and held it in 3 quarters.
  • Baird Financial Group's Fate Therapeutics position peaked at $232K in Q3 2021.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Baird Financial Group's 13F filing for Q2 2022, filed 8 Aug 2022.